Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma

8 Aug 2012

Abstract excerpt

BACKGROUND: Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome-wide profile of acquired resistance in the tumour from an exceptional case with advanced pleural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations
Share to Occupational and environmental lung diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22905093
DOI: 10.1371/journal.pone.0040521

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of MesotheliomaPMID 22905093Read ↗

Integrated genomics identify novel immunotherapy targets for malignant mesotheliomaSemantic proximity Read ↗

Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.Semantic proximity Read ↗

Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targetsSemantic proximity Read ↗

Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesotheliomaSemantic proximity Read ↗

Transcriptomics based prediction of survival and response to therapy in malignant mesotheliomaSemantic proximity Read ↗

Integrated genomics point to immune vulnerabilities in pleural mesothelioma.Semantic proximity Read ↗

The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Semantic proximity Read ↗

Recent Insights Emerging from Malignant Mesothelioma Genome SequencingSemantic proximity Read ↗

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.Semantic proximity Read ↗

CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read ↗

ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.